Şunu aradınız:: kreatininclearence (Danca - İngilizce)

(kreatininclearence ≥ 30 til < 50 ml/ min.).
the primary adjudicated endpoint was a composite of death and recurrent mi (re-mi) within 30 days of randomisation.

14% havde moderat nedsat nyrefunktion (kreatininclearence ≥ 30 til < 50 ml/ min.).
approximately 40% and 14% of patients had mild (creatinine clearance ≥ 50 to < 80 ml/ min) or moderate (creatinine clearance ≥ 30 to < 50 ml/ min) renal impairment, respectively.

den nedsatte dosis til patienter med nedsat nyrefunktion forventes at give samme auc, som er set hos patienter med kreatininclearence på 75 ml/min.
the reduced doses for patients with renal impairment are expected to achieve the same auc as that seen in patients with creatinine clearance of 75 ml/min.

når behandling med zoledronsyre påbegyndes hos patienter med myelomatose eller knoglemetastatisk skade fra faste tumorer bør serum-kreatinin og kreatininclearence (clcr) bestemmes.
when initiating treatment with zoledronic acid in patients with multiple myeloma or metastatic bone lesions from solid tumours, serum creatinine and creatinine clearance (clcr) should be determined.

når behandling med zometa initieres hos patienter med multiple myelom eller knoglemetastatisk skade fra solide tumorer bør serum- kreatinin og kreatininclearence (crcl) bestemmes.
when initiating treatment with zometa in patients with multiple myeloma or metastatic bone lesions from solid tumours, serum creatinine and creatinine clearance (crcl) should be determined.

analyser af populationsfarmakokinetik tyder på, at sunitinibs tilsyneladende clearance (cl/f) ikke er påvirket af kreatininclearence inden for det vurderede område (42-347 ml/min).
population pharmacokinetic analyses indicated that sunitinib apparent clearance (cl/f) was not affected by creatinine clearance within the range evaluated (42 - 347 ml/min).